key: cord-1019518-ssx0vdjk authors: Belančić, Andrej; Kresović, Andrea; Troskot Dijan, Marija title: Glucagon‐like peptide‐1 receptor agonists in the era of COVID‐19: Friend or foe? date: 2021-01-10 journal: Clin Obes DOI: 10.1111/cob.12439 sha: c3db6000fdb336f44256725f4f420626d320621f doc_id: 1019518 cord_uid: ssx0vdjk The aim of the present manuscript is to discuss on potential pros and cons of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) as glucose‐lowering agents during COVID‐19 pandemic, and what is more to evaluate them as potential candidates for the treatment of patients, affected by COVID‐19 infection, with or even without diabetes mellitus type 2. Besides being important glucose‐lowering agents, GLP‐1RAs pose promising anti‐inflammatory and anti‐obesogenic properties, pulmonary protective effects, as well as beneficial impact on gut microbiome composition. Hence, taking everything previously mentioned into consideration, GLP‐1RAs seem to be potential candidates for the treatment of patients, affected by COVID‐19 infection, with or even without type 2 diabetes mellitus, as well as excellent antidiabetic (glucose‐lowering) agents during COVID‐19 pandemic times. Up to October 26th 2020, the World Health Organization has recorded 42 966 344 cases of COVID-19 causing 1 152 604 deaths. Diabetes mellitus and obesity are significant and increasing worldwide health concerns, both characterized by presence of low-grade chronic inflammation and consequent immune system dysfunction leading to increased overall risk for various infections, (post)infectious complications and mortality. 1 Therefore, it is not surprising that both diabetes mellitus and obesity, in addition to arterial hypertension and old age, have been identified as most significant risk factors for COVID -19 infection and worse clinical outcomes. [2] [3] [4] Given the significance of the connection between COVID-19 and diabetes mellitus, providing the international guidelines and practical recommendations for its management during the pandemic times was of high importance. Hence, Bornstein et al. (international expert panel) provided them in the early beginnings of COVID-19 pandemic; extensively presented elsewhere. 5 It is noteworthy that no substantial considerations of potential metabolically interfering effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in suspected or COVID-19 positive patients with diabetes mellitus type 2 have been reported. 5 Only minor concern regarding potential GLP-1RAs-associated angiotensin converting enzyme-2 (ACE-2) upregulation has been raised, mostly because of the observations from a previous preclinical study on diabetes Sprague-Dawley rats. 6 is worth mentioning that GLP-1RA administration is associated with anti-obesogenic properties, a low risk of hypoglycaemia, as well as non-serious adverse events only (predominantly gastrointestinal-e.g. nausea, vomiting, diarrhoea). On top of that, liraglutide and semaglutide pose significant favourable cardiovascular benefit and are approved for use in patients with severe renal impairment (eGFR≥15). [10] [11] [12] The aim of the present narrative literature review is to discuss on potential pros and cons of GLP-1RAs as glucose-lowering agents during COVID-19 pandemic, and what is more to evaluate them as potential candidates for the treatment of patients, affected by COVID-19 infection, with or even without diabetes mellitus type 2. Finally, to conclude if GLP-1RA therapy is a friend or foe in the present pandemic times. Potential mechanisms that may increase the susceptibility for COVID-19 in patients with diabetes have extensively been proposed elsewhere by Muniyappa and Gubbi. 13 Hyperglycaemia, hypoglycaemia, as well as exposure to high glucose variability are predictors of worse/ adverse outcomes in patients hospitalized for COVID-19. 14,15 This is not unexpected since acute hyperglycaemia, hypoglycaemia, as well as hyperglycaemia post-hypoglycaemia all produce oxidative stress and are followed by enormous production of inflammatory cytokines and by enhancement of the inflammatory/infectious process. 15 Poor glycaemic control has also been connected to alterations in innatemediated and cell-mediated adaptive immunity. 16 Moreover, it is also speculated that elevated glucose levels directly promote SARS CoV-2 viral replication. 17, 18 Apicella et al. extensively overviewed the reasons for worse COVID-19 outcomes in patients with diabetes, as well as relevant studies on COVID-19 outcomes according to glycaemic control. 19 For instance, Zhu et al. in their retrospective, longitudinal, multi-centered study demonstrated that well-controlled blood glucose (glycaemic variability within 3.9 to 10.0 mmol/L) was associated with markedly lower mortality (adjusted HR 0.14) compared to poorly controlled blood glucose (upper limit of glycaemic variability exceeding 10.0 mmol/L) among patients with pre-existing type 2 diabetes during hospitalization for COVID-19. 20 An American retrospective observational study also demonstrated significantly longer length of stay and higher mortality in COVID-19 patients with diabetes and/or uncontrolled hyperglycaemia when comparing to patients without diabetes or uncontrolled hyperglycaemia. 21 What is more, Holman et al. in their population-based cohort study, of people diagnosed with diabetes who were registered with a general practice in England, reported a strong association between preceding hyperglycaemia and COVID-19 related death after adjustment for other risk factors. In people with type 2 diabetes, COVID-19 related mortality was significantly higher in those with HbA1c ≥59 mmol/mol (7.6%) than in those with an HbA1c of 48-53 mmol/mol (6.5-7.0%), and the risk increased significantly with increasing HbA1c levels (HR 1.22 for 59-74 mmol/mol [7.6-8.9%] and HR 1.36 for 75-85 mmol/mol [9.0-9.9%]). It is worth mentioning that low HbA1c (<48 mmol/mol) was also associated with significantly increased COVID-19 mortality. 22 Thus, an overly rigid glucose control is also probably not the best solution since it may increase the risk of hypoglycaemia (in hospitalized patients with diabetes), which can also result in increased length of hospitalization and in-hospital mortality. 23, 24 In addition, a retrospective study by Wang et al. highlighted fasting blood glucose (FBG) ≥7 mmol/L at admission as an independent predictor for 28-day mortality in patients with COVID-19 without previous diagnosis of diabetes. On top of that, patients with admission FBG ≥7 mmol/L and 6.1-6.9 mmol/L had higher levels of in-hospital complications when compared with patients with admission FBG <6.1 mmol/L (OR 3.99 and OR 2.61, respectively). 25 Similarly, admission blood glucose was an independent risk factor for predicting the progression to critical cases/death from non-critical cases, and initial blood glucose level of critical diagnosis was an independent risk factor for in-hospital mortality in critical cases in the study by Wu et al. Furthermore, higher median glucose level during hospital stay or after critical diagnosis was associated with poorer clinical outcomes, both in COVID-19 patients with diabetes and those without a history of diabetes. 26 Bearing previously mentioned in mind, the preferred glucose- Katsiki and Ferrannini. 30 In addition to the pancreas, expression of the GLP-1R has been detected in various cells and organs including brain, kidney, stomach, heart, endothelium, as well as lung and certain immune cells. 31 Preclinical studies suggest that GLP-1RAs lower body weight predominantly by direct interaction with diverse GLP-1R populations and by directly and indirectly affecting the activity of neural pathways involved in food intake, reward, and energy expenditure. 40 Relevant clinical data is generally consistent that long-acting GLP-1RA usage results in significant weight loss (most probably and predominantly due to modulated food preference and reduced energy intake). [41] [42] [43] [44] [45] [46] [47] [48] Change in weight with different GLP-1RAs in head-to-head clinical studies, was extensively reviewed by Trujillo et al. 49 In addition, due to clinically meaningful weight loss in patients with obesity/overweight, reductions in glycaemic variables and multiple cardiometabolic risk factors, as well as improvements in health-related quality of life demonstrated in SCALE clinical trials, liraglutide in once-daily subcutaneous dose of 3.0 mg was finally registered as Saxenda for treating obesity (body mass index -BMI ≥30 kg/m 2 ) or excess weight (BMI ≥27 kg/m 2 ) accompanied with one or more weight-related comorbidities (e.g. hypertension, dyslipidemia, diabetes), as an adjunct to diet and exercise. [42] [43] [44] [45] 50 Anti-obesogenic properties of long-acting GLP-1RAs are even more desirable now during the times of COVID-19 pandemic, since obesity is associated with increased COVID-19 susceptibility and severity due to low-grade chronic inflammation, higher expression of ACE-2 and pathway associated components, as well as decreased vitamin D bioavailability and gut microbiome dysbiosis. 51, 52 To clarify, a decrease in BMI and fat mass due to GLP-1RA usage has a beneficial effect on previously mentioned components, which finally results in reduction of overall COVID-19 susceptibility and risk for development of its more severe clinical forms. In addition to all previously described, GLP-1RAs also seem to have beneficial effect on gut microbiota. 53, 54 To elaborate, the human gut microbiota is mostly composed by two dominant bacterial phyla -Bacteroidetes (Gram-negative bacteria) and Firmicutes (mostly Gram-positive bacteria). 55 On top of that, total lipopolysaccharide (LPS) produced in the healthy human gut (Bacteroidetes contribute 79%-92.4% of the overall LPS biosynthesis) is immunosilent/immunoinhibitory (has a very limited capacity to activate TLR4 -NF-ĸB pathway and elicit the production of inflammatory cytokines). 56 Accumulating body of literature is generally consistent that individuals with diabetes mellitus type 2 and/or obesity have altered intestinal microbiota which is characterized by significantly higher level of Firmicutes and lower level of Bacteroidetes (decreased B/F ratio), compared to healthy/normal-weight individuals. 57 proinflammatory pathways (such as TLR4-NF-ĸB) due to endotoxemia (proinflammatory LPS) could be prevented during the initial step of the pathophysiological cascade described by Belanči c. 52 Besides being important glucose-lowering agents, GLP-1RAs pose promising anti-inflammatory and anti-obesogenic properties, pulmonary protective effects, as well as beneficial impact on gut microbiome composition. In conclusion, taking everything previously mentioned into consideration, GLP-1RAs seem to be potential candidates for the treatment of patients, affected by COVID-19 infection, with or even without type 2 diabetes mellitus, as well as excellent antidiabetic (glucose-lowering) agents during COVID-19 pandemic times. 70 Last but not least, it is of high importance to constantly evaluate new scientific data/evidence regarding pharmacotherapy in COVID-19 pandemic times, based on evidence-based medicine principles. ORCID Andrej Belanči c https://orcid.org/0000-0001-7848-6600 Obesity and type 2 diabetes mellitus drive immune dysfunction, infection development, and sepsis mortality Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation. Obesity (Silver Spring) Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the new York City area Practical recommendations for the management of diabetes in patients with COVID-19 Activation of the GLP-1 receptor by Liraglutide increases ACE2 expression, reversing right ventricle hypertrophy, and improving the production of SP-A and SP-B in the lungs of type 1 diabetes rats Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same? United States of America: FDA approves first oral GLP-1 treatment for type 2 diabetes Glucagon-like peptide 1 receptor agonists for type 2 diabetes Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial Semaglutide and cardiovascular outcomes in patients with type 2 diabetes The effect of glucagon-like Peptide-1 receptor agonists on renal outcomes in type 2 diabetes COVID-19 pandemic, coronaviruses, and diabetes mellitus Treating type 2 diabetes in COVID-19 patients: the potential benefits of injective therapies Issues for the management of people with diabetes and COVID-19 in ICU Diabetes, infection risk and COVID-19 Elevated glucose levels favor SARS-CoV-2 infection and monocyte response through a HIF-1α/glycolysis-dependent axis COVID-19 and diabetes mellitus: from pathophysiology to clinical management COVID-19 in people with diabetes: understanding the reasons for worse outcomes Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes Glycemic characteristics and clinical outcomes of COVID-19 patients hospitalized in the United States Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study Benefits and harms of intensive glycemic control in patients with type 2 diabetes Risk factors for hypoglycemia in patients with type 2 diabetes, hospitalized in internal medicine wards: findings from the FADOI-DIAMOND study Fasting blood glucose at admission is an independent predictor for 28-day mortality in patients with COVID-19 without previous diagnosis of diabetes: a multi-centre retrospective study Elevation of blood glucose level predicts worse outcomes in hospitalized patients with COVID-19: a retrospective cohort study Glycaemic variability in diabetes: clinical and therapeutic implications A review of GLP-1 receptor agonists: evolution and advancement, through the lens of randomised controlled trials. Diabetes Obes Metab Lowest glucose variability and hypoglycemia are observed with the combination of a GLP-1 receptor agonist and basal insulin (VARIATION study) Anti-inflammatory properties of antidiabetic drugs: A promised land in the COVID-19 era? Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences Anti-inflammatory effects of GLP-1-based therapies beyond glucose control Letter to the editor: comment on GLP-1-based drugs and COVID-19 treatment Coronavirus infections and type 2 diabetes-shared pathways with therapeutic implications Glucagon-like peptide-1 (GLP-1) reduces mortality and improves lung function in a model of experimental obstructive lung disease in female mice Glucagon-like peptide 1 signaling inhibits allergen-induced lung IL-33 release and reduces group 2 innate lymphoid cell cytokine production in vivo Liraglutide attenuates lipopolysaccharide-induced acute lung injury in mice Glucagon like Peptide-1 (GLP-1) modulates OVA-induced airway inflammation and mucus secretion involving a protein kinase a (PKA)-dependent nuclear factor-κB (NF-κB) signaling pathway in mice Long-term observational study on the impact of GLP-1R agonists on lung function in diabetic patients Semaglutide lowers body weight in rodents via distributed neural pathways Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study A randomized, controlled trial of 3.0 mg of Liraglutide in weight management Efficacy of Liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE maintenance randomized study Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE sleep apnea randomized clinical trial Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: insights from the SUSTAIN 1-7 trials Semaglutide 2.4 mg for the treatment of obesity: key elements of the STEP trials 1 to 5. Obesity (Silver Spring) GLP-1 receptor agonists: a review of head-to-head clinical studies Liraglutide (Saxenda) for weight loss Potential pathophysiological mechanisms leading to increased COVID-19 susceptibility and severity in obesity Gut microbiome dysbiosis and endotoxemia -additional pathophysiological explanation for increased COVID-19 severity in obesity A glucagon-like Peptide-1 receptor agonist lowers weight by modulating the structure of gut microbiota Featured article: structure moderation of gut microbiota in liraglutide-treated diabetic male rats A human gut microbial gene catalogue established by metagenomic sequencing Total lipopolysaccharide from the human gut microbiome silences toll-like receptor signaling Microbiota associated with type 2 diabetes and its related complications Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults A metagenome-wide association study of gut microbiota in type 2 diabetes Molecular characterisation of the faecal microbiota in patients with type II diabetes Microbial ecology: human gut microbes associated with obesity Association between body mass index and Firmicutes/Bacteroidetes ratio in an adult Ukrainian population Human intestinal microbiota composition is associated with local and systemic inflammation in obesity Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lipid-lowering therapy and renin-angiotensin-aldosterone system inhibitors in the era of the COVID-19 pandemic Liraglutide enhances the activity of the ACE-2/Ang(1-7)/mas receptor pathway in lungs of male pups from food-restricted mothers and prevents the reduction of SP-A Pharmacotherapy in COVID-19 patients: a review of ACE2-raising drugs and their clinical safety Currently prescribed drugs in the UKthat could upregulate or downregulate ACE2 in COVID-19 disease: a systematic review Diabetes and COVID-19: evidence, current status and unanswered research questions ACE2 and SARS-CoV-2 infection: might GLP-1 receptor agonists play a role? How to cite this article: Belanči c A, Kresovi c A, Troskot Glucagon-like peptide-1 receptor agonists in the era of COVID-19: Friend or foe?